OncoStem Diagnostics Pvt. Ltd. is a Bengaluru-based diagnostics company focused on developing prognostic tests that help oncologists make evidence-based, personalized cancer treatment decisions.

Founded in 2011, the company uses tumour biology and biomarker analysis to assess cancer aggressiveness and recurrence risk. Its flagship product, CanAssist Breast, is designed for people with early-stage invasive breast cancer after surgery. The test classifies the likelihood of recurrence over five years as low or high, giving doctors additional information when planning treatment and assessing whether chemotherapy may be appropriate.

OncoStem reports that the test has been validated in South Asian and Caucasian populations, and that results are available within eight business days after the laboratory receives the tissue sample. The company also highlights its AI-driven, biomarker-based approach and personalized cancer therapy support. Its services include test information, sample reports, patient and clinician resources, and direct assistance with enquiries.

OncoStem states that its diagnostics operate under CAP, NABL, and ISO 13485 standards and are supported by scientific publications and a clinical advisory board